Design, synthesis and SARs of novel salicylanilides as potent inhibitors of RANKL-induced osteoclastogenesis and bone resorption

Chun Liang Chen, Chia Chung Lee, Fei Lan Liu, Tsung Chih Chen, Ahmed Atef Ahmed Ali, Deh Ming Chang, Hsu Shan Huang

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Inhibiting osteoclastogenesis is a promising therapeutic target for treating osteoclast-related diseases. Herein, we synthesized a series of modified salicylanilides and their corresponding 3-phenyl-2H-benzo[e][1,3]oxazine-2,4(3H)-dione and 10-phenyldibenzo[b,f][1,4]oxazepin-11(10H)-one derivatives, and investigated the effects of such compounds on RANKL-induced osteoclast formation. Among them, a salicylanilide derivative (A04) and its 3-phenyl-2H-benzo[e][1,3]oxazine-2,4(3H)-dione derivative (B04) markedly suppressed RANKL-induced osteoclast differentiation and showed no significant cytotoxic effects at doses higher than that required to inhibit osteoclast formation. Both compounds reduced osteoclast formation and bone resorptive activity of osteoclasts in a dose-dependent manner. Further, the anti-osteoclastogenic effects of A04 and B04 may operate through reducing the RANKL-induced nuclear translocation of NFATc1. Accordingly, we present the potent anti-osteoclastogenic compounds A04 and B04 as promising candidates for further optimization as anti-resorptive agents.

Original languageEnglish
Pages (from-to)70-84
Number of pages15
JournalEuropean Journal of Medicinal Chemistry
Volume117
DOIs
Publication statusPublished - Jul 19 2016

Fingerprint

Salicylanilides
Osteoclasts
Bone Resorption
Osteogenesis
Bone
Oxazines
Derivatives

Keywords

  • 3-Phenyl-2H-benzo[e][1,3]oxazine-2,4(3H)-dione
  • NFATc1
  • Osteoclast
  • Salicylanilide

ASJC Scopus subject areas

  • Drug Discovery
  • Organic Chemistry
  • Pharmacology

Cite this

Design, synthesis and SARs of novel salicylanilides as potent inhibitors of RANKL-induced osteoclastogenesis and bone resorption. / Chen, Chun Liang; Lee, Chia Chung; Liu, Fei Lan; Chen, Tsung Chih; Ahmed Ali, Ahmed Atef; Chang, Deh Ming; Huang, Hsu Shan.

In: European Journal of Medicinal Chemistry, Vol. 117, 19.07.2016, p. 70-84.

Research output: Contribution to journalArticle

Chen, Chun Liang ; Lee, Chia Chung ; Liu, Fei Lan ; Chen, Tsung Chih ; Ahmed Ali, Ahmed Atef ; Chang, Deh Ming ; Huang, Hsu Shan. / Design, synthesis and SARs of novel salicylanilides as potent inhibitors of RANKL-induced osteoclastogenesis and bone resorption. In: European Journal of Medicinal Chemistry. 2016 ; Vol. 117. pp. 70-84.
@article{35f30dd458f84cae8193bfa06ad1bb55,
title = "Design, synthesis and SARs of novel salicylanilides as potent inhibitors of RANKL-induced osteoclastogenesis and bone resorption",
abstract = "Inhibiting osteoclastogenesis is a promising therapeutic target for treating osteoclast-related diseases. Herein, we synthesized a series of modified salicylanilides and their corresponding 3-phenyl-2H-benzo[e][1,3]oxazine-2,4(3H)-dione and 10-phenyldibenzo[b,f][1,4]oxazepin-11(10H)-one derivatives, and investigated the effects of such compounds on RANKL-induced osteoclast formation. Among them, a salicylanilide derivative (A04) and its 3-phenyl-2H-benzo[e][1,3]oxazine-2,4(3H)-dione derivative (B04) markedly suppressed RANKL-induced osteoclast differentiation and showed no significant cytotoxic effects at doses higher than that required to inhibit osteoclast formation. Both compounds reduced osteoclast formation and bone resorptive activity of osteoclasts in a dose-dependent manner. Further, the anti-osteoclastogenic effects of A04 and B04 may operate through reducing the RANKL-induced nuclear translocation of NFATc1. Accordingly, we present the potent anti-osteoclastogenic compounds A04 and B04 as promising candidates for further optimization as anti-resorptive agents.",
keywords = "3-Phenyl-2H-benzo[e][1,3]oxazine-2,4(3H)-dione, NFATc1, Osteoclast, Salicylanilide",
author = "Chen, {Chun Liang} and Lee, {Chia Chung} and Liu, {Fei Lan} and Chen, {Tsung Chih} and {Ahmed Ali}, {Ahmed Atef} and Chang, {Deh Ming} and Huang, {Hsu Shan}",
year = "2016",
month = "7",
day = "19",
doi = "10.1002/jcp.25304",
language = "English",
volume = "117",
pages = "70--84",
journal = "European Journal of Medicinal Chemistry",
issn = "0223-5234",
publisher = "Elsevier Masson SAS",

}

TY - JOUR

T1 - Design, synthesis and SARs of novel salicylanilides as potent inhibitors of RANKL-induced osteoclastogenesis and bone resorption

AU - Chen, Chun Liang

AU - Lee, Chia Chung

AU - Liu, Fei Lan

AU - Chen, Tsung Chih

AU - Ahmed Ali, Ahmed Atef

AU - Chang, Deh Ming

AU - Huang, Hsu Shan

PY - 2016/7/19

Y1 - 2016/7/19

N2 - Inhibiting osteoclastogenesis is a promising therapeutic target for treating osteoclast-related diseases. Herein, we synthesized a series of modified salicylanilides and their corresponding 3-phenyl-2H-benzo[e][1,3]oxazine-2,4(3H)-dione and 10-phenyldibenzo[b,f][1,4]oxazepin-11(10H)-one derivatives, and investigated the effects of such compounds on RANKL-induced osteoclast formation. Among them, a salicylanilide derivative (A04) and its 3-phenyl-2H-benzo[e][1,3]oxazine-2,4(3H)-dione derivative (B04) markedly suppressed RANKL-induced osteoclast differentiation and showed no significant cytotoxic effects at doses higher than that required to inhibit osteoclast formation. Both compounds reduced osteoclast formation and bone resorptive activity of osteoclasts in a dose-dependent manner. Further, the anti-osteoclastogenic effects of A04 and B04 may operate through reducing the RANKL-induced nuclear translocation of NFATc1. Accordingly, we present the potent anti-osteoclastogenic compounds A04 and B04 as promising candidates for further optimization as anti-resorptive agents.

AB - Inhibiting osteoclastogenesis is a promising therapeutic target for treating osteoclast-related diseases. Herein, we synthesized a series of modified salicylanilides and their corresponding 3-phenyl-2H-benzo[e][1,3]oxazine-2,4(3H)-dione and 10-phenyldibenzo[b,f][1,4]oxazepin-11(10H)-one derivatives, and investigated the effects of such compounds on RANKL-induced osteoclast formation. Among them, a salicylanilide derivative (A04) and its 3-phenyl-2H-benzo[e][1,3]oxazine-2,4(3H)-dione derivative (B04) markedly suppressed RANKL-induced osteoclast differentiation and showed no significant cytotoxic effects at doses higher than that required to inhibit osteoclast formation. Both compounds reduced osteoclast formation and bone resorptive activity of osteoclasts in a dose-dependent manner. Further, the anti-osteoclastogenic effects of A04 and B04 may operate through reducing the RANKL-induced nuclear translocation of NFATc1. Accordingly, we present the potent anti-osteoclastogenic compounds A04 and B04 as promising candidates for further optimization as anti-resorptive agents.

KW - 3-Phenyl-2H-benzo[e][1,3]oxazine-2,4(3H)-dione

KW - NFATc1

KW - Osteoclast

KW - Salicylanilide

UR - http://www.scopus.com/inward/record.url?scp=84963808202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963808202&partnerID=8YFLogxK

U2 - 10.1002/jcp.25304

DO - 10.1002/jcp.25304

M3 - Article

C2 - 27089213

AN - SCOPUS:84963808202

VL - 117

SP - 70

EP - 84

JO - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

SN - 0223-5234

ER -